Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 04:30 ET | Source: Oculis Holding AG

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to...
October 16, 2025 05:01 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

The company aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk, often before clinical symptoms appear.
October 14, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and...
October 09, 2025 09:00 ET | Source: Doheny Eye Institute

Doheny Eye Institute Announces Upcoming Presentations at the American Academy of Ophthalmology 2025 Annual Meeting

PASADENA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that 10 of its affiliated clinician-scientists have been...
October 02, 2025 09:00 ET | Source: Nacuity Pharmaceuticals, Inc.

Nacuity Pharmaceuticals Granted U.S. FDA Breakthrough Therapy Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa

FORT WORTH, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
September 25, 2025 06:15 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
September 04, 2025 13:00 ET | Source: Oculis Holding AG

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and...
September 01, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01...
August 28, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for...
August 25, 2025 04:00 ET | Source: Oculis Holding AG

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of...